Bluebird Seeks EU Fast-Track Review For Lenti-D Gene Therapy
Bluebird bio is planning to file its EU marketing application for Lenti-D this year, before it files for approval in the US in mid-2021.
Bluebird bio is planning to file its EU marketing application for Lenti-D this year, before it files for approval in the US in mid-2021.